65,437 trials
Diabetes Mellitus, Type 2
Primary: Incidence Rate of Lower Limb Amputation (LLA) — 0.40; 0.48; 0.27; 0.23 Patients with events per 100pt-yrs — p=0.9276
Invasive Breast Cancer
Primary: Change in Tumor Infiltrating Immune Cells — 2.6 fold-change of % CD45+ cells
Urinary Incontinence
Primary: Percentage of Participants That Found the Product to be Comfortable to Wear — 53 percentages of participants
Cancer · Severe Major Depression · Schizophrenia
Primary: Disruptions in Cancer Care — 37; 48; 20; 10 Participants
Obesity
Primary: Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR) — -154.36; -134.68 kilocalories per day (kcal/day) — p=0.5733
Mild Cognitive Impairment · Alzheimer's Disease
Primary: Change in Hopkins Verbal Learning Test (HVLT) Total Recall Score — -0.94; -1.65 units on a scale — p=>0.05
Migraine
Primary: Change From Baseline in the Number of Monthly Migraine Days (MMDs) — -6.2; -6.0; -4.2 days — p=0.0106
Peanut Allergy
Primary: Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Up-dosing Double-blind, Placebo-controlled Food Challenge (DBPCFC)…
Obesity
Primary: Mean Difference in Weight Loss Between Oxytocin and Placebo 8 Weeks After Baseline — 0.20; 0.26 kilogram
Malaria · Malaria,Falciparum
Primary: Number of Participants With Possibly, Probably, or Definitely Related Serious Adverse Events (SAEs) — 0; 0 Participants
Cystic Fibrosis · Dysbiosis
Primary: Shannon Index — 5.02; 4.96; 5.28; 5.73 Shannon index
Hyperemesis Gravidarum · Nausea Gravidarum · Vomiting of Pregnancy
Primary: Time to Symptom Control — 72; 87 minutes
Migraine
Primary: Change in Migraine Disability Assessment Scale (MIDAS) Score — -25.1; 6.9 score on a scale
Hemodialysis Catheter Infection
Primary: Bacteraemia Rate — 2; 1 episodes — p=1.00
Depression · Bipolar Disorder · Anxiety Disorders
Primary: Clinical Global Improvement Scale (CGIS) — 14; 20 Participants